{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:12:28Z","timestamp":1787508748707,"version":"build-2736575974"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomed J"],"published-print":{"date-parts":[[2014]]},"DOI":"10.4103\/2319-4170.125885","type":"journal-article","created":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T07:16:27Z","timestamp":1397114187000},"page":"90","source":"Crossref","is-referenced-by-count":31,"title":["Serum levels of melatonin and cytokines in multiple sclerosis"],"prefix":"10.1016","volume":"37","author":[{"given":"Naser","family":"Farhadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrbanoo","family":"Oryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Nabiuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"key-10.4103\/2319-4170.125885-1","first-page":"345","volume-title":"MEG mapping in multiple sclerosis patients","author":"Kotini","year":"2007","journal-title":"Eura Medicophys"},{"key":"key-10.4103\/2319-4170.125885-2","first-page":"365","volume-title":"The influence of immunomodulation on psycho-neuroimmunological functions in benign multiple sclerosis","author":"Haase","year":"2004","journal-title":"Neuroimmunomodulation"},{"key":"key-10.4103\/2319-4170.125885-3","unstructured":"Janeway CA, Travers P, Walport M, Shlomchik MJ. Immunobiology. New York: Garland Science; 2005."},{"key":"key-10.4103\/2319-4170.125885-4","first-page":"3068","volume-title":"Antioxidants and neuroprotection in the adult and developing central nervous system","author":"Kaur","year":"2008","journal-title":"Curr Med Chem"},{"key":"key-10.4103\/2319-4170.125885-5","first-page":"177","volume-title":"Human pineal physiology and functional significance of melatonin","author":"Macchi","year":"2004","journal-title":"Front Neuroendocrinol"},{"key":"key-10.4103\/2319-4170.125885-6","first-page":"5","volume-title":"Melatonin defeats neurally-derived free radicals and reduces the associated neuromorphological and neurobehavioral damage","author":"Reiter","year":"2007","journal-title":"J Physiol Pharmacol"},{"key":"key-10.4103\/2319-4170.125885-7","first-page":"467","volume-title":"The immunotherapeutic potential of melatonin","author":"Maestroni","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"key-10.4103\/2319-4170.125885-8","first-page":"273","volume-title":"Benign multiple sclerosis is characterized by a stable neuroimmunologic network","author":"Haase","year":"2004","journal-title":"Neuroimmunomodulation"},{"key":"key-10.4103\/2319-4170.125885-9","first-page":"1503","volume-title":"Role of melatonin in mood disorders and the antidepressant effects of agomelatine","author":"Srinivasan","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"key-10.4103\/2319-4170.125885-10","first-page":"253","volume-title":"Influence of personality on the relationship between gray matter volume and neuropsychiatric symptoms in multiple sclerosis","author":"Benedict","year":"2013","journal-title":"Psychosom Med"},{"key":"key-10.4103\/2319-4170.125885-11","first-page":"73","volume-title":"Hypothesis: Are beta-blockers safe for patients with multiple sclerosis?","author":"Fares","year":"2013","journal-title":"Int J Nutr Pharmacol Neurol Dis","ISSN":"https:\/\/id.crossref.org\/issn\/2231-0738","issn-type":"print"},{"key":"key-10.4103\/2319-4170.125885-12","first-page":"1977","volume-title":"Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism","author":"Robinson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/2319-4170.125885-13","first-page":"i94","volume-title":"Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system","author":"Selmaj","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/2319-4170.125885-14","first-page":"1548","volume-title":"Anti-Tumor Necrosis Factor Alpha-Associated Multiple Sclerosis","author":"Titelbaum","year":"2005","journal-title":"Am J Neuroradiol"},{"key":"key-10.4103\/2319-4170.125885-15","first-page":"S180","volume-title":"The role of melatonin in the pathogenesis of multiple sclerosis: A case-control study","author":"Ghorbani","year":"2013","journal-title":"Int J Prev Med","ISSN":"https:\/\/id.crossref.org\/issn\/2008-7802","issn-type":"print"},{"key":"key-10.4103\/2319-4170.125885-16","first-page":"272","volume-title":"Melatonin and the immune system in aging","author":"Cardinali","year":"2008","journal-title":"Neuroimmunomodulation"},{"key":"key-10.4103\/2319-4170.125885-17","first-page":"992","volume-title":"Human lymphocyte-synthesized melatonin is involved in the regulation of the interleukin-2\/interleukin-2 receptor system","author":"Carrillo-Vico","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2319-4170.125885-18","first-page":"574","volume-title":"Melatonin enhances IL-2, IL-6, and IFN-\u03b3 production by human circulating CD4+cells: A possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes","author":"Garcia-Mauri\u00f1o","year":"1997","journal-title":"J Immunol"},{"key":"key-10.4103\/2319-4170.125885-19","first-page":"327","volume-title":"In vitro effects of melatonin on mitogen-induced lymphocyte proliferation and cytokine expression in young and old rats","author":"Pahlavani","year":"1997","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"key-10.4103\/2319-4170.125885-20","first-page":"163","volume-title":"Cytokines in multiple sclerosis: From bench to bedside","author":"Imitola","year":"2005","journal-title":"Pharmacol Ther"}],"container-title":["Biomedical Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T22:58:24Z","timestamp":1538693904000},"score":1,"resource":{"primary":{"URL":"http:\/\/biomedj.cgu.edu.tw\/pdfs\/2014\/37\/2\/images\/BiomedJ_2014_37_2_90_125885.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"alternative-id":["125885"],"URL":"https:\/\/doi.org\/10.4103\/2319-4170.125885","relation":{},"ISSN":["2319-4170"],"issn-type":[{"value":"2319-4170","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}